Release date: 2015-09-16
In a research paper published in the international journal Cellular and Molecular Gastroenterology and Hepatology , researchers from the University of Hiroshima said that the detection of circulating tumor DNA in pre-operative serum samples may help predict hepatocellular carcinoma in patients. Early recurrence and help guide the progression of the disease; hepatocellular carcinoma is a common type of liver cancer, which is also the leading cancer in the world that causes cancer death.
Researcher Atsushi Ono said that we found that the level of circulating tumor DNA can accurately reflect the progression of hepatocellular carcinoma and the effects of therapies. With further research, the identification of genomic properties by analysis of circulating tumor DNA or It can help guide individualized therapy and management strategies. The researchers sequenced the entire genome of 46 patients undergoing hepatocellular carcinoma resection therapy, and obtained serum samples from patients before and after surgery. The researchers then compared the normal DNA and tumor cell DNA of the patient's body. Differences were found in DNA mutations in all 46 samples.
When mutations were present in all tumors, the researchers detected the presence of circulating tumor DNA only in the serum of 7 patients, and the presence of circulating tumor DNA was directly associated with tumor size increase and tumor recurrence within 2 years after resection; The level of circulating tumor DNA can also increase as the disease progresses and can help reflect the response of the therapy. Hepatocellular carcinoma is usually detected in the late stages of the patient, and the patient's 5-year survival rate is only 11%, so identifying a new method may help monitor disease progression and identify those who benefit from therapy. Patients, of course, are critical to improving survival in patients with stem cell cancer.
Finally, Dr. Jerrold R. Turner said that the analysis of circulating tumor DNA can reflect the transformation of the potential pattern of individualized therapy for liver cancer. We hope that more research can be done later to obtain more encouraging value to help ultimately improve the treatment of malignant hepatocytes. An effective treatment for cancer.
Source: Bio Valley
staff and provides patients with a high-quality hospital experience. At the same time, the company maintains long-term close cooperation with universities and large medical groups, and enters the medical engineering industry such as
medical intelligent sharing and accompanying systems, medical logistics storage systems, and operating room purification systems.
Emergency Trolley,Stainless Stell Trolley,Mobile Emergency Trolley Carrying Drugs,Emergency Trolley With Drawers And Wheels
Shanghai Rocatti Biotechnology Co.,Ltd , https://www.shljdmedical.com